Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays.
The identification of new biomarkers is essential in the implementation of personalized health care strategies that offer new therapeutic approaches with optimized and individualized treatment. In support of hypothesis generation and testing in the course of our biomarker research an online portal and respective function-tested reverse transcription quantitative real-time PCR assays (RT-qPCR) facilitated the selection of relevant biomarker genes. We have established workflows applicable for convenient high throughput gene expression analysis in biomarker research with cell lines (in vitro studies) and xenograft mouse models (in vivo studies) as well as formalin-fixed paraffin-embedded tissue (FFPET) sections from various human research and clinical tumor samples. Out of 92 putative biomarker candidate genes selected in silico, 35 were shown to exhibit differential expression in various tumor cell lines. These were further analysed by in vivo xenograft mouse models, which identified 13 candidate genes including potential response prediction biomarkers and a potential pharmacodynamic biomarker. Six of these candidate genes were selected for further evaluation in FFPET samples, where optimized RNA isolation, reverse transcription and qPCR assays provided reliable determination of relative expression levels as precondition for differential gene expression analysis of FFPET samples derived from projected clinical studies. Thus, we successfully applied function tested RT-qPCR assays in our biomarker research for hypothesis generation with in vitro and in vivo models as well as for hypothesis testing with human FFPET samples. Hence, appropriate function-tested RT-qPCR assays are available in biomarker research accompanying the different stages of drug development, starting from target identification up to early clinical development. The workflow presented here supports the identification and validation of new biomarkers and may lead to advances in efforts to achieve the goal of personalized health care.
Roche Applied Science, Roche Diagnostics GmbH, Penzberg, Germany. sabine.lohmann@roche.com
Sabine
S
Lohmann
Andrea
A
Herold
Tobias
T
Bergauer
Anton
A
Belousov
Gisela
G
Betzl
Mark
M
Demario
Manuel
M
Dietrich
Leopoldo
L
Luistro
Manuela
M
Poignée-Heger
Kathy
K
Schostack
Mary
M
Simcox
Heiko
H
Walch
Xuefeng
X
Yin
Hua
H
Zhong
Martin
M
Weisser
D000818:Animals; D054316:Biomarkers, Pharmacological / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000378:metabolism; D018076:DNA, Complementary / Q000235:genetics; D055808:Drug Discovery / Q000379:methods*; D005404:Fixatives; D005557:Formaldehyde; D015870:Gene Expression; D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D016612:Paraffin Embedding; D057285:Precision Medicine; D012313:RNA / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D023041:Xenograft Model Antitumor Assays
D054316:Biomarkers, Pharmacological; D014408:Biomarkers, Tumor; D018076:DNA, Complementary; D005404:Fixatives; D005557:Formaldehyde; D012313:RNA